Compare Charles River Laboratories Intl. Inc (CRL) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs ArcelorMittal SA — how do they compare? Charles River Laboratories Intl. Inc trades at $302.01 (market cap $14.23B), while ArcelorMittal SA trades at $64.23 (market cap $45.70B). The key difference: ArcelorMittal SA is far larger — about 3.2× Charles River Laboratories Intl. Inc's market cap, and ArcelorMittal SA pays a 0.98% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and ArcelorMittal SA for 36 Days on average.
| CRL | MT | |
|---|---|---|
Market Cap | $14.23B | $45.70B |
Volume | 1,176,885 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $310.77 | $78.74 |
52-Week Low | $149.93 | $36.91 |
Typical Hold Time | 33 Days | 36 Days |
Enterprise Value | $17.06B | $55.27B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
ArcelorMittal (MT) trades at $62.32, down 4.4% on the day, amid a bearish technical setup and recent operational disruptions in Ukraine. The stock shows mixed fundamentals with a low P/S of 0.75 and P/B of 0.84, but profitability metrics like net margin (2.88%) and ROE (3.32%) remain modest. Recent Q2 2026 earnings missed estimates, though Q1 and Q4 2025 beat expectations. Analyst consensus is bullish with a $74.33 price target, but technical indicators signal caution.
The outlook is clouded by near-term headwinds including the Ukraine plant impairment and volatile steel demand, yet long-term value is supported by low valuation multiples and strategic regionalization efforts. Risks include geopolitical exposure and cyclical industry pressures, but institutional sentiment remains positive with 52% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
